Core Viewpoint - The healthcare sector, particularly the CXO industry, is experiencing a strong recovery driven by stable global outsourcing demand and the success of blockbuster drugs like GLP-1, with significant performance from leading companies in the sector [3]. Group 1: Market Performance - On March 31, the overall market faced adjustments, but the AH healthcare sector showed resilience, with representative healthcare ETFs (512170 and 159137) initially rising over 2% [1]. - The CXO concept stocks performed well against the market trend, with Kailaiying's A-shares hitting the daily limit and closing up 13.54% in Hong Kong [1]. - Zhaoyan New Drug's A-shares initially reached the daily limit, closing up 6.54%, while its Hong Kong shares surged over 15% before closing up 0.67% [1]. Group 2: Company Performance - Kailaiying reported a net profit of 1.132 billion yuan for 2025, reflecting a year-on-year increase of 19.35% [1]. - Zhaoyan New Drug achieved a net profit of 298 million yuan for 2025, a threefold increase year-on-year, despite a nearly 18% decline in revenue [1][2]. - Among the healthcare ETFs, 6 out of 8 A-share CXO leading companies have disclosed annual reports, with three companies (Zhaoyan New Drug, Tigermed, and WuXi AppTec) showing over 100% year-on-year net profit growth [2]. Group 3: Industry Trends - The Hong Kong healthcare ETF (159137) includes 9 leading CXO stocks, with 7 companies reporting double-digit net profit growth and 4 companies exceeding 100% growth [3]. - The CXO industry is undergoing a "leading companies leading the way, structural differentiation" recovery, with a trend of resources and orders concentrating towards larger leading firms [3]. - The industry is characterized by a preference for CDMO over CRO and larger enterprises over small and medium-sized companies [3].

Group 1 - CXO leading companies reported better-than-expected annual results, with Zhaoyan New Drug achieving a net profit of nearly 300 million yuan in 2025, a year-on-year increase of 300% [1][4] - Kailaiying reported revenue and net profit growth, with a net profit of 1.132 billion yuan, representing a year-on-year increase of 19.35% [1][4] - The AH medical sector saw a rise, with medical ETFs (512170) and Hong Kong Stock Connect medical ETF Huabao (159137) both increasing over 2% at one point, and A-shares hitting the limit up [1][4] Group 2 - The CXO content in medical ETFs (512170) and Hong Kong Stock Connect medical ETF Huabao (159137) is 25% and 42%, respectively [2][5] - The Zhejiang Merchants Pharmaceutical team analyzed that the CXO industry is undergoing a clearing process, and they are optimistic about domestic leading CDMO companies and CRO companies benefiting from the recovery of domestic demand [2][5] - The analysis indicates that the fundamental turning point for CXO has appeared and is expected to continue to recover [2][5]

Core Viewpoint - The A-share market has shown active trading with significant focus on sectors like chemicals and non-ferrous metals, driven by price increases and strong performance in ETFs related to these sectors [1][2]. Group 1: Market Performance - The A-share market closed February with the Shanghai Composite Index achieving three consecutive monthly gains, with daily trading volumes exceeding 1 trillion yuan becoming a norm [1]. - On February 27, the total trading volume in the Shanghai, Shenzhen, and Beijing markets reached 2.51 trillion yuan, slightly down by 504 billion yuan from the previous day [1]. - Over 3,200 stocks in the market saw gains, with notable performances in small metals and rare earths, leading to a surge in stocks like Hunan Gold [1]. Group 2: Sector Highlights - The non-ferrous metals sector continued to perform strongly, with the non-ferrous ETF (159876) reaching a peak increase of 3.82% and closing up 3.74% on the day [4]. - The chemical sector benefited from rising prices, with the chemical ETF (516020) achieving four consecutive daily gains, marking its highest point since January 2022 [1][4]. - The AI sector is gaining traction, with domestic AI usage surpassing that of the US, benefiting the domestic AI industry chain, as reflected in the performance of the innovation-focused AI ETF (589520) [1]. Group 3: ETF Performance - The electric power ETF (159146) saw a significant increase of 2.64%, reaching a new high since its listing, driven by the rising demand for electricity due to AI development [2][10]. - The largest medical ETF (512170) in the market rose by 1.14%, recovering its annual line, with a net inflow of over 1.9 billion yuan in the previous three days [14][16]. - The electric power sector is viewed as a defensive investment amid the AI boom, with the electric power ETF focusing on various energy sources including thermal, hydro, wind, nuclear, and solar power [12]. Group 4: Future Outlook - Analysts suggest that the non-ferrous metals sector still has upward momentum, supported by supply disruptions and high demand, with a focus on precious, industrial, battery, and strategic metals [7]. - The medical sector is expected to recover, with growth opportunities arising from performance recovery, overseas expansion, brain-computer interfaces, and AI in healthcare [16][18].

Group 1 - The A-share medical sector showed positive performance on February 27, with the largest medical ETF (512170) rising by 1.14% and successfully recovering the annual line, with a transaction volume of 384 million CNY [1][9] - The ETF experienced continuous premium trading, indicating a positive buying sentiment, with over 190 million CNY net subscriptions in the previous three days [1][9] - The leading stock, Huatai Medical, surged by 8.24%, with its performance report indicating over 20% year-on-year growth in revenue and net profit for 2025 [1][11] Group 2 - The Hong Kong medical sector rebounded after several days of decline, with the Hong Kong medical ETF (159137) recovering from a historical low, ending a six-day losing streak [3][11] - CXO companies, particularly those under WuXi AppTec, showed strong performance, with shares rising by 8.23% for WuXi AppTec, 5% for WuXi Biologics, and 3.21% for WuXi AppTec [3][11] - Citic Securities remains optimistic about the growth potential and space for the CXO sector due to increasing overseas orders and a gradual recovery in domestic demand [4][12] Group 3 - In the medical device industry, Citic Securities believes that policy impacts will eventually clear, and companies will gradually recover after strategic adjustments, suggesting an allocation increase in 2026 [6][14] - Investment opportunities are expected to arise from performance recovery, international expansion, brain-computer interfaces, and AI medical applications [6][14] - The medical ETF fund size reached 27.7 billion CNY, making it the largest in the medical sector, covering various themes including brain-computer interfaces and innovative medical devices [7][14]

Market Overview - A-shares ended February with the Shanghai Composite Index achieving three consecutive monthly gains, with active trading continuing post-Spring Festival, where daily trading volumes exceeding 1 trillion yuan have become the norm [1] - On February 27, the three major A-share indices showed mixed results, with over 3,200 stocks rising and a total trading volume of 2.51 trillion yuan, a slight decrease of 504 billion yuan from the previous day [1] Sector Performance - The focus on price increase themes has intensified, with notable performances in the chemical and non-ferrous metal sectors [1] - The rare earth sector continues to see price increases, with stocks like Hunan Gold hitting the daily limit, and the non-ferrous ETF (159876) reaching a peak increase of 3.82% [1][4] - The chemical ETF (516020) has achieved four consecutive daily gains, reaching its highest point since January 2022, driven by the phosphoric chemical sector and TDI market trends [1] AI and Computing Power - The computing power sector remains active, with China's AI token usage surpassing that of the US for the first time, indicating potential benefits for domestic AI industry chains [1] - The domestic AI industry is expected to benefit from increased demand for computing power, with the AI-focused ETF (589520) rising by 2.03% [1] - The cloud computing sector is entering a price increase cycle, with the big data ETF (516700) seeing a significant rise of 2.05% [1] Electricity Sector - The electricity sector is experiencing a surge, with the electricity ETF (159146) rising by 2.64%, reaching a new high since its listing [2][10] - The demand for electricity is expected to increase alongside AI development, making it a defensive investment in the current market environment [2][12] - The "HALO trading" phenomenon is driving the electricity sector, as physical assets like energy and electricity are deemed indispensable in the face of AI advancements [12] Healthcare Sector - The healthcare sector is showing signs of recovery, with the largest healthcare ETF (512170) rising by 1.14% and successfully reclaiming its annual line [14] - The healthcare ETF has seen significant net subscriptions, totaling over 1.9 billion yuan in the past three days [14] - The performance of leading healthcare stocks, such as WuXi AppTec, is contributing to the sector's positive momentum, with expected revenue growth exceeding 20% [16] Investment Recommendations - Companies are advised to focus on three main areas: globally priced cyclical goods like chemicals and non-ferrous metals, manufacturing sectors related to technology and national strength, and technology sectors entering performance realization periods [3] - The healthcare sector is recommended for investment due to its recovery potential and growth opportunities in areas like AI healthcare and brain-computer interfaces [18]

Group 1 - The medical sector showed strong performance with the largest medical ETF (512170) initially rising over 1% and maintaining positive momentum, outperforming the broader market [1] - Over 1.15 billion CNY of net subscriptions were recorded for the medical ETF, indicating strong investor interest [1] - The ETF has a total scale of 27.7 billion CNY, making it the largest in the medical and healthcare category [3] Group 2 - Huatai Medical reported an expected revenue of 2.584 billion CNY for 2025, representing a year-on-year increase of 25%, with net profit projected at 821 million CNY, up 22% [3] - Other companies within the medical ETF, such as United Imaging and Yirui Technology, are also expected to see net profit growth exceeding 40% [3] - The medical ETF consists of over 50% medical device weight and more than 25% CXO content, covering 12 AI medical and brain-machine interface concept stocks [3] Group 3 - The performance of constituent stocks within the ETF varied, with Huatai Medical leading the gains, rising nearly 7%, while major stocks like Mindray and United Imaging saw declines of nearly 1% [2][3]

Core Viewpoint - The healthcare sector is experiencing positive momentum, with the largest healthcare ETF (512170) showing strong performance and attracting significant net inflows of over 1.15 billion yuan in recent trading sessions [1][5]. Group 1: ETF Performance - The healthcare ETF (512170) initially rose over 1% and maintained a positive trend, outperforming the broader market [1]. - As of February 24, 2026, the healthcare ETF has a total fund size of 27.7 billion yuan, making it the largest in the healthcare sector [5]. Group 2: Company Earnings Reports - Huatai Medical reported an expected revenue of 2.584 billion yuan for 2025, representing a year-on-year growth of 25%, with a net profit of 821 million yuan, up 22% [3][4]. - Other companies within the ETF, such as United Imaging and Yirui Technology, also reported significant net profit growth rates exceeding 40% [3]. Group 3: Market Trends - The healthcare sector is characterized by a mix of rising and falling stocks, with Huatai Medical leading gains by rising nearly 7% after a strong earnings report, while major stocks like Mindray and United Imaging saw declines of nearly 1% [1][3].

Group 1 - The A-share pharmaceutical sector rebounded, with medical device stocks and AI healthcare concepts leading the gains, including Meinian Health and Lepu Medical rising over 3% [1] - The largest medical ETF in the market (512170) saw a near 1% increase, with a net subscription of 77.77 million yuan on the previous day [1][5] - A new policy from the Beijing-Tianjin-Hebei region aims to enhance clinical trial efficiency and reduce compliance costs for CXO and medical device companies, set to take effect on March 1, 2026 [3] Group 2 - The pharmaceutical sector stabilized, with innovative drug concepts showing mixed results; Sanofi's stock rose over 3%, while Dizhe Pharmaceutical fell over 4% [3] - The only ETF tracking the pharmaceutical index (562050) turned positive during trading [3] - The FDA's recent announcement to establish a single pivotal clinical trial as the default standard for new drug approvals is expected to shorten development cycles and lower capital costs, benefiting innovative drug companies [4]

Group 1 - The A-share pharmaceutical sector has rebounded, with medical device stocks and AI healthcare concepts leading the gains, including significant increases in companies like Meinian Health and Lepu Medical [1][8] - The largest medical ETF in the market (512170) saw a nearly 1% increase, with a net subscription of 77.77 million yuan the previous day [1][8] - A new policy from the Beijing-Tianjin-Hebei region is expected to benefit CXO and medical device companies by improving clinical trial efficiency and reducing compliance costs [2][5][10] Group 2 - The FDA has announced a new default standard for drug approvals, allowing for a single key clinical trial plus confirmatory evidence, which is projected to shorten development cycles and reduce capital costs significantly [4][12] - The cost of a single key trial is estimated to range from 30 million to 150 million USD, which will enhance the research efficiency of innovative drug companies [4][12] - The medical ETF (512170) has over 50% weight in medical devices and more than 25% in CXO, covering 12 AI medical and brain-computer interface concept stocks [4][12] Group 3 - The pharmaceutical sector is stabilizing, with mixed performance among innovative drug concepts; companies like Sanofi and Dizhiyuan have shown notable fluctuations [2][10] - Traditional Chinese medicine stocks have generally risen, with companies like Darentang and Jilin Aodong seeing increases of over 2% [2][10] - The only ETF tracking the pharmaceutical index (562050) turned positive during trading, indicating a recovery in the sector [2][10]

Group 1 - A-shares opened lower and experienced significant adjustments, while the pharmaceutical sector showed resilience by performing well in the market [1] - The National Medical Products Administration announced on February 4 that during the 14th Five-Year Plan period, there will be strong support for the innovation and development of the biomanufacturing industry, transitioning the pharmaceutical industry from "follow-up innovation" to "systematic innovation" [1][3] - Analysts are optimistic about the Chinese medicine sector, expecting valuation recovery and performance improvement driven by policy support, cost improvements, and adjustments to the essential drug catalog [3] Group 2 - The raw material drug sector is viewed positively, with expectations of price recovery after several years of price declines, supported by rising prices of bulk commodities and upstream chemicals [3] - The medical ETF, the largest in the market, had a scale of 27.5 billion yuan as of February 3, 2026, indicating strong investor interest [3] - The pharmaceutical sector showed mixed performance, with innovative drug concepts mostly declining, while traditional Chinese medicine leaders like Darentang and Pizaihuang saw significant gains [5]